Abstract:Age-dependent neurodegenerative diseases progressively form aggregates containing both shared components (e.g., TDP-43, phosphorylated tau) and proteins specific to each disease. We investigated whether diverse neuropathies might have additional aggregation-prone proteins in common, discoverable by proteomics. Caenorhabditis elegans expressing unc-54p/Q40::YFP, a model of polyglutamine array diseases such as Huntington's, accrues aggregates in muscle 2-6days posthatch. These foci, isolated on antibody-coupled magnetic beads, were characterized by high-resolution mass spectrometry. Three Q40::YFP-associated proteins were inferred to promote aggregation and cytotoxicity, traits reduced or delayed by their RNA interference knockdown. These RNAi treatments also retarded aggregation/cytotoxicity in Alzheimer's disease models, nematodes with muscle or pan-neuronal A(1-42) expression and behavioral phenotypes. The most abundant aggregated proteins are glutamine/asparagine-rich, favoring hydrophobic interactions with other random-coil domains. A particularly potent modulator of aggregation, CRAM-1/HYPK, contributed <1% of protein aggregate peptides, yet its knockdown reduced Q40::YFP aggregates 7286% (P<10(-6)). In worms expressing A(1-42), knockdown of cram-1 reduced -amyloid 60% (P<0.002) and slowed age-dependent paralysis >30% (P<10(-6)). In wild-type worms, cram-1 knockdown reduced aggregation and extended lifespan, but impaired early reproduction. Protection against seeded aggregates requires proteasome function, implying that normal CRAM-1 levels promote aggregation by interfering with proteasomal degradation of misfolded proteins. Molecular dynamic modeling predicts spontaneous and stable interactions of CRAM-1 (or human orthologs) with ubiquitin, and we verified that CRAM-1 reduces degradation of a tagged-ubiquitin reporter. We propose that CRAM-1 exemplifies a class of primitive chaperones that are initially protective and highly beneficial for early reproduction, but ultimately impair aggregate clearance and limit longevity.

Yeast Proteins may Reversibly Aggregate like Amphiphilic Molecules

Simple Model Study of Phase Transition Properties of Isolated and Aggregated Protein

Profiling the physiological impact of aberrant folded-state protein filamentation in cells

Protein rescue from aggregates by powerful molecular chaperone machines

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

Protein aggregation: An overview

Structural stability and dynamics of an amyloid-forming peptide GNNQQNY from the yeast prion sup-35

Threonine-rich carboxyl-terminal extension drives aggregation of stalled polypeptides

Model for amorphous aggregation processes

Solid-to-liquid phase transition in the dissolution of cytosolic misfolded-protein aggregates

Model Study of Prionlike Folding Behavior in Aggregated Proteins

Osmotic stress induces formation of both liquid condensates and amyloids by a yeast prion domain

Effect Of Amino Acid Sequence Rearrangment On Prion Aggregation: Molecular Dynamics Simulations Of An Amyloid-Forming Peptide From The Yeast Prion Sup35p

Phase separation of a yeast prion protein promotes cellular fitness

Sequence determinants of the aggregation of proteins within condensates generated by liquid-liquid phase separation

Polymorphism Of Amyloid Fibrils Formed By A Peptide From The Yeast Prion Protein Sup35: Afm And Tip-Enhanced Raman Scattering Studies

Phase Separation in Regulation of Aggrephagy

Prevention of amyloid‐like aggregation as a driving force of protein evolution

LLMs predict protein phases

Sequence dependent aggregation of peptides and fibril formation

Unraveling the Mechanism of Protein Disaggregation Through a ClpB-DnaK Interaction